Investment House LLC Sells 12,165 Shares of Gilead Sciences, Inc. $GILD

Investment House LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 74.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,232 shares of the biopharmaceutical company’s stock after selling 12,165 shares during the quarter. Investment House LLC’s holdings in Gilead Sciences were worth $631,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Lmcg Investments LLC boosted its stake in shares of Gilead Sciences by 0.5% in the 3rd quarter. Lmcg Investments LLC now owns 17,602 shares of the biopharmaceutical company’s stock worth $2,624,000 after buying an additional 90 shares during the last quarter. Vest Financial LLC grew its holdings in shares of Gilead Sciences by 0.4% in the third quarter. Vest Financial LLC now owns 24,851 shares of the biopharmaceutical company’s stock worth $3,704,000 after acquiring an additional 111 shares during the period. PFS Partners LLC grew its holdings in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 96 shares during the period. Bender Robert & Associates increased its position in Gilead Sciences by 8.9% during the third quarter. Bender Robert & Associates now owns 3,069 shares of the biopharmaceutical company’s stock valued at $457,000 after acquiring an additional 250 shares during the last quarter. Finally, Trifecta Capital Advisors LLC increased its position in Gilead Sciences by 12.5% during the third quarter. Trifecta Capital Advisors LLC now owns 3,602 shares of the biopharmaceutical company’s stock valued at $537,000 after acquiring an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Thursday, October 8th. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Barclays reduced their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $159.81.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the insider owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Down 0.7%

Shares of Gilead Sciences stock opened at $156.04 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock’s 50-day simple moving average is $149.10 and its 200-day simple moving average is $137.85. Gilead Sciences, Inc. has a 52 week low of $114.02 and a 52 week high of $160.51.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.01 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Inflammation pipeline expanded: Gilead agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including HCXT-2001, for approximately $1.275 billion in cash. The drug is intended for inflammatory bowel disease and could be developed alone or alongside Gilead’s emvistegrast, strengthening the company’s longer-term growth prospects. Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001
• Positive Sentiment: HIV development update: An ongoing study of a potential weekly oral HIV treatment adds another option to Gilead’s long-acting HIV portfolio. Positive clinical progress could support the company’s dominant HIV franchise and future revenue durability. Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower
• Positive Sentiment: Oncology collaboration: BioNTech and Gilead will test Gilead’s sacituzumab govitecan with BioNTech’s pumitamig in a global Phase 3 trial for advanced triple-negative breast cancer. The collaboration may improve the commercial potential of Gilead’s oncology platform, although clinical success remains uncertain. BioNTech, Gilead to Test Drug Combination
• Positive Sentiment: Favorable analyst and earnings expectations: TD Cowen reiterated a Buy view, while analysts indicated that Gilead could beat expectations in its upcoming quarterly report. Such forecasts support sentiment, though they are not guarantees of results. Gilead Sciences Receives a Buy from TD Cowen
• Neutral Sentiment: Gilead plans to present new data on rare liver diseases at The Liver Meeting 2026. The presentations could generate future catalysts, but no immediate clinical results were reported. Gilead to Present New Liver-Disease Data
• Negative Sentiment: Legal overhang: Gilead will pay $45 million to settle Texas Medicaid claims alleging unlawful incentives to encourage providers to prescribe its medicines. The financial cost is modest relative to Gilead’s size, but the settlement adds regulatory and reputational risk. Gilead Sciences to Pay $45 Million in Texas Medicaid Settlement

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.